Macrogenics (FRA:M55) Institutional Ownership: 40.50% (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
53 GF Score
Price €3.48
GF Value €3.39
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Macrogenics Institutional Ownership?

Macrogenics FRA:M55 -6.45% 53 Institutional Ownership is 40.50% as of Jul. 26, 2026. GuruFocus rates FRA:M55 with a GF Score™ of 53/100 and a GF Value™ of €3.39 (Fairly Valued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Macrogenics's institutional ownership is 40.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Macrogenics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Macrogenics's Float Percentage Of Total Shares Outstanding is 96.48%.

Macrogenics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Macrogenics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics Institutional Ownership Chart

Macrogenics Historical Data

The historical data trend for Macrogenics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 34.46 34.25 34.21 32.95 33.01 33.17 32.69 32.44 32.18 40.50
FRA:M55
53GF Score
Macrogenics Inc FRA:M55
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 40.50% mean?
Macrogenics (FRA:M55) has a Institutional Ownership of 40.50% as of Jul. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Macrogenics and its competitors.
Is Macrogenics' Institutional Ownership too high?
Macrogenics' current Institutional Ownership is 40.50%. Overall, Macrogenics has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Institutional Ownership compare to RNAC and CNXU?
Macrogenics' Institutional Ownership of 40.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Macrogenics and its competitors. Macrogenics's current Institutional Ownership is 40.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Fairly Valued. The stock's GF Value™ is €3.39, compared to a current price of €3.48 — trading 2.7% above its estimated fair value. The current Institutional Ownership is 40.50%. Macrogenics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Institutional Ownership is 40.50% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.48 is trading 2.7% above its estimated GF Value™ of €3.39. GuruFocus considers Macrogenics to be Fairly Valued.

Key valuation signals for FRA:M55:

  • Institutional Ownership: 40.50%
  • GF Value™: €3.39 vs. price of €3.48 (2.7% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
53GF Score

Get the complete analysis for FRA:M55

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price
€3.39
GF Value